App-Quantinova.ai

Association between BMI and residual estradiol levels in post-menopausal women using adjuvant letrozole: Results of a prospective study

DW Cescon - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Anastrozole

Value-based approach to treatment of HER2-positive breast cancer: Examining the evidence

NA Nixon - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab emtansine

Rates of successful engraftment in breast cancer xenograft models based on tissue type: Primary vs relapsed disease

W-l den Brok - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Results from a randomized placebo-controlled phase 2 trial evaluating exemestane i enzalutamide in patients with hormone receptorpositive breast cancer

I Krop - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Enzalutamide

MicroRNAs associated with acquired taxane resistance in a breast cancer cell line model

KJ Taylor - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Paclitaxel

Cost-effectiveness of pre-implantation genetic diagnosis for BRCA mutation carriers

JH Lipton - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Plasma osteoprotegerin and the risk of breast cancer in and mutation carriers

J Kotsopoulos - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)

A Schneeweiss - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

Expression of LAG-3 in breast cancer, and its association with subtype and outcome

S Burugu - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

10-year follow-up and biomarker discovery for adjuvant endocrine therapy; results of the TEAM trial

EJ Blok - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Exemestane

Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index

NM Iyengar - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Tumor RNA disruption index as a tool to predict response to neoadjuvant chemotherapy in breast cancer: Optimizing timing of biopsy

A Samkari - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Hypofractionated nodal radiotherapy (RT) did not increase arm morbidity compared to conventional fractionated nodal RT

N Leong - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Interplay of Prostaglandin E2 and Major Histocompatibility Comeplex-II Determines Immunoprivilege of Allogeneic Mesenchymal Stem Cells in the Ischemic Heart

Glen Lester Sequiera - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

Dinoprostone

Application of Omics to Assess the Inter Passage Variability in the Immunoprivilege of Mesenchymal Stem Cells

Glen Lester Sequiera - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

First Trimester Human Umbilical Cord Perivascular Cells (FTM HUCPVCs) Show Superior Angiogenic Potential in Angiogenic Potency Assays When Compared to Term HUCPVCs and Bone Marrow Stromal Cells

Peter Szaraz - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Ischemic injury

N/A

Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814

KS Albain - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Tamoxifen

Cardiomyocyte GSK-3? Signaling Exacerbate Pressure Overload-induced Dilated Cardiomyopathy and Heart Failure

Hind Lal - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Dilated cardiomyopathy

Tamoxifen

PI3K? Regulates Biomechanical Stress-induced Cytoskeletal Remodeling: A Critical Role of Gelsolin

Pavel Zhabyeyev - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Dilated cardiomyopathy

Phosphatidylinositol

Naringenin Supplementation of a Low-Fat Diet Enhances the Reversal of Metabolic Dysfunction, Promotes Atherosclerosis Regression and Improves Lesion Pathology in Ldlr-/- Mice

Brian G Sutherland - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Hypercholesterolemia, Familial, 1

N/A

Filters

28841 Abstracts